NASDAQ$TCRX
Tscan Therapeutics Inc · Q2 2022 earnings
Q2 2022 earnings · · Investor relations
Briefing
Reported financial results for the second quarter and provided business updates.
TScan Therapeutics reported a revenue of $4.1 million for the second quarter, primarily driven by research activities related to the collaboration agreement with Novartis. The company's cash and cash equivalents totaled $125.6 million, sufficient to fund operations into 2024. Net loss for the quarter was $15.1 million.
- Phase 1 umbrella trial for hematologic malignancies is open for enrollment.
- Publication in Cell further validates use of foundational technology to identify novel tumor antigens and effective TCRs.
- TSC-200-A2 (HPV) and TSC-204-C7 (MAGE-A1) IND filings are anticipated by year-end 2022.
- Debora Barton, M.D., was appointed as Chief Medical Officer.
Headline financials
Revenue & EPS history
Tscan Therapeutics · Revenue · Quarterly
$4.06M
Revenue by segment
Tscan Therapeutics · $4.06M total across 1 segment · Q2 2022
- Collaboration & License$4.06M—100.0%
Forward guidance
TScan Therapeutics anticipates several near-term catalysts, including providing an update on the Phase 1 umbrella trial for TSC-100 and TSC-101 by the end of 2022, progressing IND-enabling studies for solid tumor programs, and submitting IND applications for two TCRs by the end of 2022.
Tailwinds
- Progressing IND-enabling studies for solid tumor programs.
- Submitting IND applications for two TCRs by the end of 2022, including TSC-200-A2 for HPV and TSC-204-C7 for MAGE-A1.
- Filing additional INDs for solid tumor programs by the end of 2023.
- Releasing initial clinical data for TCRs in the solid tumor series by the end of 2023.
- Existing cash and cash equivalents are expected to fund operating expenses and capital expenditure requirements into 2024.
Headwinds
- Up to 40% of patients who receive HCT with RIC relapse within two years, at which point there are limited treatment options and poor prognosis.
- The company reported a net loss of $15.1 million for the second quarter ended June 30, 2022.
- Research and development expenses increased by $3.7 million compared to the same quarter in the previous year.
- General and administrative expenses increased by $2.1 million compared to the same quarter in the previous year.
- The company's future success depends on the successful development and commercialization of its TCR-T therapy candidates, which are subject to numerous risks and uncertainties.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q2 2022
+1.6%
Avg return
Earnings day
+0.2%
Avg return
5 days after
-5.7%
Avg return
30 days after
60%
12 / 20 earnings
Positive
+32.4%
Q1 2023
Best reaction
-18.2%
Q2 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +3.3% | -3.3% | -18.9% | |
| Q4 2025 | +4.9% | +19.8% | -2.4% | |
| Q3 2025 | +0.8% | -20.5% | -17.2% | |
| Q2 2025 | +3.1% | +11.8% | +14.9% | |
| Q1 2025 | -4.6% | +0.8% | +18.3% | |
| Q4 2024 | +2.6% | +7.7% | -7.1% | |
| Q3 2024 | -7.9% | -22.6% | -47.0% | |
| Q2 2024 | -1.0% | -3.0% | -3.9% | |
| Q1 2024 | +16.3% | +16.2% | +14.9% | |
| Q4 2023 | +1.6% | -6.7% | +0.9% | |
| Q3 2023 | +3.0% | +14.9% | +50.8% | |
| Q2 2023 | -4.2% | -2.3% | +12.1% | |
| Q1 2023 | +32.4% | +18.5% | -14.4% | |
| Q4 2022 | -8.5% | -23.0% | -33.3% | |
| Q3 2022 | -0.4% | +3.9% | -20.6% | |
| Q2 2022 | -10.8% | -18.8% | -20.5% | |
| Q1 2022 | +10.6% | +38.3% | +80.0% | |
| Q4 2021 | +7.8% | -1.6% | -37.8% | |
| Q3 2021 | +2.2% | -4.4% | -28.0% | |
| Q2 2021 | -18.2% | -21.7% | -53.7% | |
| Q1 2021 | — | — | — | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro